Revvity, Inc. (RVTY) is attracting renewed buying interest following its recent pullback. The stock remains in a healthy uptrend, continuing to make higher highs and higher lows while trading above the well-aligned 20- and 50-day moving averages.
Revvity, Inc. is a $12.50 billion market cap life sciences company that provides health science solutions, technologies, expertise, and services spanning the entire healthcare workflow—from discovery and drug development to diagnosis and patient care. The company specializes in translational multi-omics technologies, biomarker identification, imaging, screening, diagnostics, and informatics. It operates through two business segments: Life Sciences, which focuses on accelerating drug discovery and development, and Diagnostics, which provides instruments, reagents, assay platforms, and software for reproductive health, immunodiagnostics, applied genomics, and emerging market diagnostics.
RVTY is a narrow economic moat company that has grown both revenue and EPS in two of the last three quarters. The company reported an operating margin of 12% and a net margin of 6%. It generated a 3% return on equity (ROE) and a 2% return on invested capital (ROIC). Its balance sheet remains healthy, with a current ratio of 1.7x and a debt-to-equity ratio of 0.5x.
While profitability and returns on capital remain modest, the stock's constructive technical setup, combined with improving financial performance, suggests that the recent pullback may offer an attractive entry opportunity for trend-following investors.
Revvity, Inc. is a $12.50 billion market cap life sciences company that provides health science solutions, technologies, expertise, and services spanning the entire healthcare workflow—from discovery and drug development to diagnosis and patient care. The company specializes in translational multi-omics technologies, biomarker identification, imaging, screening, diagnostics, and informatics. It operates through two business segments: Life Sciences, which focuses on accelerating drug discovery and development, and Diagnostics, which provides instruments, reagents, assay platforms, and software for reproductive health, immunodiagnostics, applied genomics, and emerging market diagnostics.
RVTY is a narrow economic moat company that has grown both revenue and EPS in two of the last three quarters. The company reported an operating margin of 12% and a net margin of 6%. It generated a 3% return on equity (ROE) and a 2% return on invested capital (ROIC). Its balance sheet remains healthy, with a current ratio of 1.7x and a debt-to-equity ratio of 0.5x.
While profitability and returns on capital remain modest, the stock's constructive technical setup, combined with improving financial performance, suggests that the recent pullback may offer an attractive entry opportunity for trend-following investors.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.